From Mouse Mammary Tumor Model to New Therapeutic Method ---Mammary Tumor Development in Balb/c-Trp53+/- Mice and Magnetic Nanoparticle Induced Heating for Cancer Treatment

PATHWAYS CONTRIBUTING TO DEVELOPMENT OF SPONTANEOUS MAMMARY TUMORS IN BALB/c-Trp53+/- MICE Mutation and loss of p53 function are common features among human breast cancers. We use BALB/c-Trp53+/- mice as a model to examine the sequence of events leading to mammary tumors. Mammary epithelium proliferation rates were similar in both BALB/c-Trp53+/- mice and wild type controls. Among the 28 mammary tumors collected from BALB/c-Trp53+/- mice, loss of heterozygosity for Trp53 was detected in more than 90% of invasive mammary tumors. Transplantation of Trp53+/- ductal hyperplasias indicated an association between loss of the wild type allele of Trp53 and progression to invasive carcinomas. Expression of biomarkers such as ERα, PR, Her2/Neu and activated Notch1 varied among the tumors suggesting that multiple oncogenic events collaborate with loss of p53 function. The majority of the tumors expressed both luminal and basal cytokeratins (59%). Gene expression analysis showed ligands and receptors of stem cell related pathways, such as Notch and Wnt, were increased in the tumors. These results indicate that mammary tumors in BALB/c Trp53+/- mice might initiate from bipotent mammary progenitor cells. USING MAGNETIC NANOPARTICLES FOR CANCER THERMOTHERAPY Alternating magnetic field (AMF) heating of magnetic nanomaterials provides a promising method for executing therapeutic thermal treatment for cancer patients. In order to explore the potential of magnetic nanoparticles (MNPs) for hyperthermia treatment, we synthesized iron oxide MNPs with various passivation by citric acid, folate, trimethylamine carboxylic acid, or albumin. The albumin passivated MNP (MNP-A) surpassed other MNPs, showing efficient heating with very low inherent cytotoxicity. Confocal microscopy located MNP-A (FITC tagged) accumulation in both cell nucleus and cytosol after 24hr incubation with HeLa cells. The quantity of cell bound MNP-A (including internalized and cell membrane bound MNP-A) was positively associated with MNP-A concentration and incubation time with cells. The MNP-A bound to cells was sufficient to increase the temperature in the cell pellet Δ7°C after 8min exposure to AMF. No significant temperature increase or cell death was detected in control groups. Our data demonstrate that MNP-A provides a selective tool for AMF-induced thermal treatment, as well as useful dosing information for future preclinical animal studies

Regulation of cancer stem cells by p53

The hypothesis that cancer stem cells are responsible for the chemoresistant and metastatic phenotypes of many breast cancers has gained support using cell-sorting strategies to enrich the tumor-initiating population of cells. The mechanisms regulating the cancer stem cell pool, however, are less clear. Two recent publications suggest that loss of p53 permits expansion of presumptive cancer stem cells in mouse mammary tumors and in human breast cell lines. These results add restriction of cancer stem cells as a new tumor suppressor activity attributed to p53

Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice

INTRODUCTION Treatment with estrogen and progesterone (E+P) mimics the protective effect of parity on mammary tumors in rodents and depends upon the activity of p53. The following experiments tested whether exogenous E+P primes p53 to be more responsive to DNA damage and whether these pathways confer resistance to mammary tumors in a mouse model of Li-Fraumeni syndrome. METHODS Mice that differ in p53 status (Trp53+/+, Trp53+/-, Trp53-/-) were treated with E+P for 14 days and then were tested for p53-dependent responses to ionizing radiation. Responses were also examined in parous and age-matched virgins. The effects of hormonal exposures on tumor incidence were examined in BALB/c-Trp53+/- mammary tissues. RESULTS Nuclear accumulation of p53 and apoptotic responses were increased similarly in the mammary epithelium from E+P-treated and parous mice compared with placebo and age-matched virgins. This effect was sustained for at least 7 weeks after E+P treatment and did not depend on the continued presence of ovarian hormones. Hormone stimulation also enhanced apoptotic responses to ionizing radiation in BALB/c-Trp53+/- mice but these responses were intermediate compared with Trp53+/+ and Trp-/- tissues, indicating haploinsufficiency. The appearance of spontaneous mammary tumors was delayed by parity in BALB/c-Trp53+/- mice. The majority of tumors lacked estrogen receptor (ER), but ER+ tumors were observed in both nulliparous and parous mice. However, apoptotic responses to ionizing radiation and tumor incidence did not differ among outgrowths of epithelial transplants from E+P-treated donors and nulliparous donors. CONCLUSION Therefore, E+P and parity confer a sustained increase in p53-mediated apoptosis within the mammary epithelium and suppress mammary tumorigenesis, but this effect was not retained in epithelial outgrowths.This work was supported by grants from the US Army Medical Research and Materiel Command (W81XWH0410385 to KAD and DAMD17-01-1-0315 to ACB) and the National Institutes of Health (RO1-CA095164 to DJJ)

Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice

Introduction Treatment with estrogen and progesterone (E+P) mimics the protective effect of parity on mammary tumors in rodents and depends upon the activity of p53. The following experiments tested whether exogenous E+P primes p53 to be more responsive to DNA damage and whether these pathways confer resistance to mammary tumors in a mouse model of Li-Fraumeni syndrome. Methods Mice that differ in p53 status (Trp53+/+, Trp53+/-, Trp53-/-) were treated with E+P for 14 days and then were tested for p53-dependent responses to ionizing radiation. Responses were also examined in parous and age-matched virgins. The effects of hormonal exposures on tumor incidence were examined in BALB/c-Trp53+/- mammary tissues. Results Nuclear accumulation of p53 and apoptotic responses were increased similarly in the mammary epithelium from E+P-treated and parous mice compared with placebo and age-matched virgins. This effect was sustained for at least 7 weeks after E+P treatment and did not depend on the continued presence of ovarian hormones. Hormone stimulation also enhanced apoptotic responses to ionizing radiation in BALB/c-Trp53+/- mice but these responses were intermediate compared with Trp53+/+ and Trp-/- tissues, indicating haploinsufficiency. The appearance of spontaneous mammary tumors was delayed by parity in BALB/c-Trp53+/- mice. The majority of tumors lacked estrogen receptor (ER), but ER+ tumors were observed in both nulliparous and parous mice. However, apoptotic responses to ionizing radiation and tumor incidence did not differ among outgrowths of epithelial transplants from E+P-treated donors and nulliparous donors

Changes in mammary gland architecture induced by estrogen and progesterone

Tissues from mice that were nulliparous , E+P-treated , and parous were examined using whole mounts and 4-μm sections stained with hematoxylin and eosin . Magnifications, × 4 and × 100 . E+P, estrogen and progesterone.<p><b>Copyright information:</b></p><p>Taken from "Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-mice"</p><p>Breast Cancer Research : BCR 2008;10(3):R43-R43.</p><p>Published online 12 May 2008</p><p>PMCID:PMC2481490.</p><p></p

Estrogen receptor-alpha expression in spontaneous mammary tumors in mice

Spontaneous mammary tumors from nulliparous and parous BALB/c-mice were stained with anti-ERα antibodies. Representative sections are shown for mammary intra-epithelial neoplasias (MIN) and adenocarcinomas that differ in ERα status. The tissues from nulliparous mice include ERαMIN, ERαadenocarcinoma, and ERαadenocarcinoma. The tissues from parous mice include ERαMIN, ERαadenocarcinoma, and ERαadenocarcinoma. Scale bar = 20 μm. ERα, estrogen receptor-alpha.<p><b>Copyright information:</b></p><p>Taken from "Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-mice"</p><p>http://breast-cancer-research.com/content/10/3/R43</p><p>Breast Cancer Research : BCR 2008;10(3):R43-R43.</p><p>Published online 12 May 2008</p><p>PMCID:PMC2481490.</p><p></p

A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells

Basal-like triple-negative breast cancers (TNBCs) have poor prognosis. To identify basal-like TNBC dependencies, a genome-wide siRNA lethality screen compared two human breast epithelial cell lines transformed with the same genes: basal-like BPLER and myoepithelial HMLER. Expression of the screen’s 154 BPLER dependency genes correlated with poor prognosis in breast, but not lung or colon, cancer. Proteasome genes were overrepresented hits. Basal-like TNBC lines were selectively sensitive to proteasome inhibitor drugs relative to normal epithelial, luminal, and mesenchymal TNBC lines. Proteasome inhibition reduced growth of established basal-like TNBC tumors in mice and blocked tumor-initiating cell function and macrometastasis. Proteasome addiction in basal-like TNBCs was mediated by NOXA and linked to MCL-1 dependence. •Basal-like TNBC cell lines are addicted to the proteasome and MCL-1•Proteasome inhibition blocks T-IC functions in basal-like TNBCs•Proteasome addiction in these cells is mediated by NOXA and linked to MCL-1•Proteasome inhibitors inhibit basal-like tumor growth and metastasis in mic

Transcriptional Responses to Estrogen and Progesterone in Mammary Gland Identify Networks Regulating p53 Activity

Estrogen and progestins are essential for mammary growth and differentiation but also enhance the activity of the p53 tumor suppressor protein in the mammary epithelium. However, the pathways by which these hormones regulate p53 activity are unknown. Microarrays were used to profile the transcriptional changes within the mammary gland after administration of either vehicle, 17β-estradiol (E), or progesterone (P) individually and combined (EP). Treatment with EP yielded 1182 unique genes that were differentially expressed compared to the vehicle-treated group. Although 30% of genes were responsive to either E or P individually, combined treatment with both EP had a synergistic effect accounting for 60% of the differentially regulated genes. Analysis of protein-protein interactions identified p53, RelA, Snw1, and Igfals as common targets of genes regulated by EP. RelA and p53 form hubs within a network connected by genes that are regulated by EP and that may coordinate the competing functions of RelA and p53 in proliferation and survival of cells. Induction of early growth response 1 (Egr1) and Stratifin (Sfn) (also known as 14–3-3σ) by EP was confirmed by reverse transcription-quantitative PCR and shown to be p53 independent. In luciferase reporter assays, Egr1 was shown to enhance transcriptional activation by p53 and inhibit nuclear factor κB activity. These results identify a gene expression network that provides redundant activation of RelA to support proliferation as well as sensitize p53 to ensure proper surveillance and integration of their competing functions through factors such as Egr1, which both enhance p53 and inhibit RelA